Home / Resource Library / Ibrutinib Treatment in Waldenstrom’s Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATE Study

Ibrutinib Treatment in Waldenstrom’s Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATE Study

Long term follow up of a phase III trial of Ibrutinib for treating Waldenstrom’s Macroglobulinemia.